In the USA, there is intensive discussion about whether marijuana could be legalized or legally reclassified in 2026. The question engages politicians, activists, and business representatives equally and divides public opinion. While some states have already advanced their own legalization processes, the federal level remains a critical point in this debate.
Rescheduling marijuana – for example from Schedule I to a lower category – would have significant implications for research, medical applications, and commercial activities. Proponents argue with scientific evidence and economic opportunities, while critics raise concerns about safety and regulation. 2026 could be an important turning point if political majorities shift or new administrations change course.
These developments in the USA are also of interest to the European and Swiss cannabis industry, as regulatory decisions in other countries often shape and influence international discussions. Further information on the current situation can be found in our source index.
